Biogen, Inc.
https://www.biogen.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Biogen, Inc.
Relyvrio’s Failure Sparks NeuroSense ALS Development Changes
NeuroSense plans to adjust its upcoming clinical trial to avoid the fate of Amylyx’s ALS candidate, which was recently withdrawn from the market due to a lack of efficacy.
Biogen, Ionis End ALS Program; Ionis Will Advance Angelman Asset Alone
Development has ended for BIIB105 in ALS after it failed to clear a crucial biomarker and show clinical benefit. Also, Biogen opted not to advance ION582 for Angelman syndrome, so Ionis will go it alone.
Pharma Facing Growing Risks From Geopolitics, Industry Leaders Warn
Industry leaders and experts at the Financial Times Pharma and Biotech Summit said the US relationship with China adds pressing risk to pharma.
Pharma Facing Growing Risks From Geopolitics, Industry Leaders Warn
Industry leaders and experts at the Financial Times Pharma and Biotech Summit said the US relationship with China adds pressing risk to pharma.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
-
- Biogen Idec
- Convergence Pharmaceuticals Ltd
- Nightstar Therapeutics plc
- Stromedix, Inc.
- Syntonix Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice